Compounded Semaglutide Impurity Studies: The 2026 Independent Testing Round-Up

A handful of independent labs, university researchers, and pharmacy oversight groups have published testing data on compounded semaglutide over the past 18 months. The findings are less alarming than tabloid coverage suggests — but there are patterns worth knowing before you pick a pharmacy.

What Independent Testing Actually Looks For

When a lab tests a compounded semaglutide sample, it typically evaluates four things: potency (does the product actually contain the labeled amount of semaglutide?), identity (is it semaglutide at all, or a related peptide?), impurities (what else is in there, and at what levels?), and sterility (was it prepared under sterile conditions?). Each of these can fail independently — a product can be sterile and correctly identified but under-potent, for example.

Impurity Categories Reported

Reported impurities in compounded semaglutide fall into a few categories. Process-related impurities include leftover reagents from peptide synthesis. Related substances are semaglutide fragments or variants (des-amino forms, oxidation products, deamidation products). Excipient artifacts come from the formulation ingredients rather than the active. And in a small number of cases, contamination from unrelated peptides or non-peptide substances has been reported when API sourcing was compromised.

Most independent testing has found products that pass acceptable impurity thresholds. The problem cases — where impurities were above reasonable limits or where the wrong peptide was present entirely — have concentrated at a small number of pharmacies with poor API sourcing, not across the compounded market as a whole.

Potency Findings

Potency variance is the most commonly reported issue. Reasonable target is ±10% of labeled potency. Some independent testing has found products at 85–95% of label (under-potent) and, less commonly, above 105% (over-potent). Under-potency at the low end is why some patients feel their compounded product "isn't working the same" as a brand-name equivalent — the actual delivered dose may be lower than expected.

What Pharmacy Behavior Correlates With Better Results

Pharmacies that publish or share Certificates of Analysis on request tend to correlate with cleaner independent test results. So do pharmacies that name their API sources, participate in accreditation programs (PCAB, ACHC), and use third-party independent labs for potency verification (rather than only in-house testing).

If a pharmacy won't share a CoA on request, or if the CoA it shares is generic (not batch-specific), that's a data point worth weighing. Not disqualifying on its own, but worth stacking against other signals.

How to Use Testing Data Without Overreacting

Independent testing findings are useful signal but shouldn't drive panic. Brand-name products also have specified impurity limits — the question is whether a compounded product meets reasonable standards, not whether it's identical to brand. For most patients on well-sourced compounded product, the difference is within margins that don't affect clinical outcome. For patients on poorly-sourced product, the differences can be meaningful enough to warrant switching.

Where to Start